Ludwig Bauer
@ludwig-bauer.bsky.social
Scientist at Roche in chemical proteomics | Interested in drug discovery and interdisciplinary research | Oxford PhD
Reposted by Ludwig Bauer
Reposted by Ludwig Bauer
New in @science.org 🧬
What if an enzyme you thought you knew turned out to control metabolism in a completely new way?
We found that NUDT5 acts as a molecular handbrake on purine synthesis, reshaping how cells make DNA building blocks and respond to cancer drugs.
www.science.org/doi/10.1126/...
What if an enzyme you thought you knew turned out to control metabolism in a completely new way?
We found that NUDT5 acts as a molecular handbrake on purine synthesis, reshaping how cells make DNA building blocks and respond to cancer drugs.
www.science.org/doi/10.1126/...
A non-enzymatic role of Nudix hydrolase 5 in repressing purine de novo synthesis
Folate metabolism is intricately linked to purine de novo synthesis through the incorporation of folate-derived one-carbon units into the purine scaffold. By investigating chemical and genetic depende...
www.science.org
November 6, 2025 at 7:30 PM
New in @science.org 🧬
What if an enzyme you thought you knew turned out to control metabolism in a completely new way?
We found that NUDT5 acts as a molecular handbrake on purine synthesis, reshaping how cells make DNA building blocks and respond to cancer drugs.
www.science.org/doi/10.1126/...
What if an enzyme you thought you knew turned out to control metabolism in a completely new way?
We found that NUDT5 acts as a molecular handbrake on purine synthesis, reshaping how cells make DNA building blocks and respond to cancer drugs.
www.science.org/doi/10.1126/...
Reposted by Ludwig Bauer
A small molecule targeting the circadian regulator BMAL1 is developed, enabling dose-dependent modulation of gene expression for circadian-controlled genes and downregulation of inflammatory pathways in macrophages
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Pharmacological targeting of BMAL1 modulates circadian and immune pathways - Nature Chemical Biology
The authors developed a small molecule targeting the circadian regulator BMAL1, enabling dose-dependent modulation of gene expression for circadian-controlled genes and downregulation of inflammatory ...
www.nature.com
March 27, 2025 at 2:28 PM
A small molecule targeting the circadian regulator BMAL1 is developed, enabling dose-dependent modulation of gene expression for circadian-controlled genes and downregulation of inflammatory pathways in macrophages
www.nature.com/articles/s41...
www.nature.com/articles/s41...